美诺华子公司获得非布司他片药品注册证书

Core Viewpoint - Meinuo Pharma (603538.SH) has received approval from the National Medical Products Administration for its drug Febuxostat tablets, which are intended for the long-term treatment of hyperuricemia in gout patients [1] Group 1 - The drug is developed by Meinuo Pharma's wholly-owned subsidiary, Ningbo Meinuo TianKang Pharmaceutical Co., Ltd [1] - The approval signifies a significant milestone for the company in expanding its product portfolio in the pharmaceutical market [1]